Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 1,251,259 shares of the medical research company's stock, valued at approximately $92,631,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.21% of Edwards Lifesciences at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Sivik Global Healthcare LLC acquired a new position in Edwards Lifesciences in the 4th quarter worth $3,702,000. Farmers & Merchants Investments Inc. grew its position in shares of Edwards Lifesciences by 21.1% during the 4th quarter. Farmers & Merchants Investments Inc. now owns 134,341 shares of the medical research company's stock valued at $9,945,000 after buying an additional 23,409 shares during the last quarter. Lockheed Martin Investment Management Co. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $4,499,000. Union Bancaire Privee UBP SA acquired a new stake in Edwards Lifesciences in the fourth quarter worth $1,120,000. Finally, United Asset Strategies Inc. lifted its stake in Edwards Lifesciences by 5.2% in the fourth quarter. United Asset Strategies Inc. now owns 168,159 shares of the medical research company's stock valued at $12,449,000 after buying an additional 8,242 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW traded up $0.36 during trading hours on Friday, hitting $78.09. 9,018,091 shares of the company were exchanged, compared to its average volume of 5,183,185. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a market cap of $45.81 billion, a price-to-earnings ratio of 11.20, a P/E/G ratio of 4.82 and a beta of 1.12. The firm's fifty day moving average is $73.22 and its 200 day moving average is $72.33.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company's revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.66 EPS. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Barclays lifted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Truist Financial cut their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. Finally, Citigroup restated a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $80.20.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares of the company's stock, valued at approximately $2,153,526.69. This represents a 27.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,442 shares of company stock worth $4,025,799. Company insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.